159 related articles for article (PubMed ID: 23406774)
1. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
Pritchard AL; Hayward NK
Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
[TBL] [Abstract][Full Text] [Related]
2. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
3. Emerging Raf inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
[TBL] [Abstract][Full Text] [Related]
4. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
6. Targeting BRAF in melanoma: biological and clinical challenges.
MandalĂ M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
7. Emerging BRAF inhibitors for melanoma.
Sabbatino F; Wang Y; Wang X; Ferrone S; Ferrone CR
Expert Opin Emerg Drugs; 2013 Dec; 18(4):431-43. PubMed ID: 24073999
[TBL] [Abstract][Full Text] [Related]
8. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
9. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase inhibitors in melanoma.
Eigentler TK; Meier F; Garbe C
Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
Alcalá AM; Flaherty KT
Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
[TBL] [Abstract][Full Text] [Related]
12. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
13. BRAF inhibitors and melanoma.
Flaherty KT
Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Halilovic E; Solit DB
Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
[TBL] [Abstract][Full Text] [Related]
15. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.
Dillon R; Nilsson CL; Shi SD; Lee NV; Krastins B; Greig MJ
J Proteome Res; 2011 Nov; 10(11):5084-94. PubMed ID: 21936566
[TBL] [Abstract][Full Text] [Related]
17. On or off target: mutations, models, and predictions.
Garraway LA; Hahn WC
Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.
Savoia P; Zavattaro E; Cremona O
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419275
[TBL] [Abstract][Full Text] [Related]
19. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
20. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]